Pharmacodynamic monitoring of cancer chemotherapy: Childhood acute lymphoblastic leukemia as a model

Therapeutic Drug Monitoring

Volumn 20, Issue 5, 1998, Pages 453-458

  Yates, Charles R ^a   Pui, Ching Hon ^a   Evans, William E ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Pharmacodynamics

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAUNORUBICIN; LYMPHOCYTE ANTIGEN RECEPTOR; METHOTREXATE; PREDNISONE; T LYMPHOCYTE RECEPTOR; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CONFERENCE PAPER; DRUG MONITORING; GENE REARRANGEMENT; HUMAN; INTRATHECAL DRUG ADMINISTRATION; LEUKEMIA CELL; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CHILD; DRUG MONITORING; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MODELS, BIOLOGICAL;

EID: 0031715034     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199810000-00001     Document Type: Conference Paper

References (42)

1. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of a relation between concentration and effect. N Engl J Med 1986;314:471-7.
2. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990;336:225-9.
3. Pui C-H, Evans WE. Acute leukemia. N Engl J Med. 1998;339:in press.
4. Pui C-H, Crist WM. Biology and treatment of acute lymphoblastic leukemia. J Pediatr 1994;124:491-503.
5. Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18:273-9.
6. Miller DR, Leikin S, Albo V, Sather H, Karon M, Hammond D. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141: a report from childrens cancer study group. Cancer 1983;51:1041-9.
7. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337:61-6.
8. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996;14:389-98.
9. Reiter A, Schrappe M, Wolf-Dieter L, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusion of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
10. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Hamatol Bluttransfus 1990;33:439-50.
11. Arico M, Basso G, Mandelli F, et al. Good steroid response in vivo predicts favorable outcome in children with T-cell acute lymphoblastic leukemia. (AEIOP). Cancer 1995;75:1684-93.
12. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86:1292-5.
13. Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994;94:1996-2001.
14. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J Clin Invest 1996;97:73-80.
15. Bokkerink JPM, Bakker MAH, Hulscher TW, De Abreu RA, Schretlen EDAM. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 1988;37: 2321-7.
16. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J, eds. Determinants of drug responsiveness. In: The Anticancer Drugs. New York: Oxford University Press; 1994:26.
17. Goldie J, Coldman A. Genetic instability in the development of drug resistance. Semin Oncol 1985;12:222-30.
18. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;81:2215-22.
19. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85:1416-34.
20. Van Dongen JJM, Hooijkaas J, Adriaansen HJ, Hahlen K, Van Zanen GE. Detection of minimal residual acute lymphoblastic leukemia by immunological marker analysis: possibilities and limitations. In: Hagenbeek A, Lowenberg B, eds. Minimal Residual Disease in Acute Leukemia. Netherlands: Nijhoff; 1986:113.
21. Janossy G, Campana D, Burnett A, et al. Autologous bone marrow transplantation in acute lymphoblastic leukemia - preclinical immunologic studies. Leukemia 1988;2:485-95.
22. Coustan-Smith E, Behm FG, Hurwitz CA, River GK, Campana D. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993;7:853-8.
23. Orfao A, Ciudad J, Lopez-Berges MC, et al. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. Leuk Lymphoma 1994;13:87-90.
24. Griesinger F, Piro-Noack M, Falk M, et al. High predictive value for relapse by three-color-flow-cytometric detection of leukemia-associated immunophenotype (LAIP) positive cells in acute lymphoblastic leukemia (ALL). Blood 1996;88(suppl 1):478a.
25. Coustan-Smith E, Behm FG, Raimondi SC, Rubnitz JE, Pui C-H, Campanu D. Immunologic detection of minimal residual disease in childhood acute lymphoblastic leukemia: a prospective study. Blood 1996:88(suppl 1):478a.
26. Groffen J, Stephenson JR, Heisterkamp N, De Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93-9.
27. Heisterkamp N, Stam K, Groffen J, De Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985;315:758-61.
28. Pui CH, Christ WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990;76:1449-63.
29. Fey MF, Kulozik AE, Hansen-Hagge TE, Tobler A. The polymerase chain reaction: a new tool for detection of minimal residual disease in haematological malignancies. Eur J Cancer 1991;27: 89-94.
30. Potter MN. The detection of minimal residual disease in acute lymphoblastic leukemia. Blood Rev 1992;6:68-82.
31. Lewis S, Gellert M. The mechanism of antigen receptor gene assembly. Cell 1989;59:585-8.
32. Lacy MJ, McNeil LK, Roth ME, Kranz LM. T-cell receptor delta chain diversity in peripheral lymphocytes. Proc Natl Acad Sci USA 1989;86:1023-6.
33. Van Dongen JJM, Wolvers-Tettero ILM. Analysis of immunoglobulin and T cell receptor genes, I: basic and technical aspects. Clin Chim Acta 1991;198:1-91.
34. Beishuizen A, Verhoeven MA, van Wering ER, Hahlen K, Hooijkaas J, van Dongen JJ. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994;83: 2238-47.
35. Steward CG, Goulden NJ, Katz F, et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994; 83:1355-62.
36. Wasserman R, Galili N, Yoshinori I, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992;10:1879-88.
37. Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343:196-200.
38. Gruhen B, Yi H, Kitchingman GR, Hongeng S. Low to undetectable levels of minimal residual disease using a semi-nested polymerase chain reaction after intensive induction therapy in childhood B-lineage acute lymphoblastic leukemia. Blood 1996;88 (suppl 1):478a.
39. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997; 336:317-23.
40. Nizet Y, Van Daele S, Lewalle P, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 1993;82:1618-25.
41. Cave H, Guidai C, Rohrlich P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 1994;83:1892-1902.
42. Evans WE, Relling MV, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.